Posters

Clinical outcomes after bilateral implantation of a trifocal intraocular lens compared to an enhanced-depth-of-focus (EDOF) intraocular lens

Poster Details

First Author: G.Auffarth GERMANY

Co Author(s):    D. Varadi   H. Wallek   D. Breyer   H. Kaymak   K. Klabe   F. Kretz     

Abstract Details

Purpose:

To compare the bilateral visual acuity outcomes and photic disturbances of a trifocal IOL (AT LISA tri 839MP/939MP, Carl Zeiss Meditec, Germany) with a EDOF IOL (Symfony, AMO, USA).

Setting:

IVCRC.NET Research Group, Dept. of Ophthalmology, University of Heidelberg, Breyer, Klaymak & Klabe Augenchirurgie D�Ã�¼sseldorf and Augen�Ã�¤rzte Dr. Gerl & Kollegen Ahaus, Germany

Methods:

35 patients were enrolled in this multi-center prospective observational study, 20 patients implanted with a trifocal IOL (AT LISA tri 839MP/939MP) and 15 patients implanted with a EDOF IOL (Symfony). All patients were examined 6-24 months postoperatively and clinical data was collected on: Uncorrected visual acuities at near, intermediate and far distance (UNVA, UIVA, UDVA) under mesopic and photopic light conditions using low contrast (10%) and high contrast (100%) visual acuity charts; Defocus Curve; Glare & Halo simulation tests.

Results:

The photopic VA outcomes on UNVA(10%), UNVA(100%), UIVA(10%), UIVA(100%), UDVA(100%), are 0.27�Â�±0.18; 0.03�Â�±0.14; 0.21�Â�±0.18; 0.03�Â�±0.17; 0.07�Â�±0.07, respectively in the trifocal group and 0.30�Â�±0.12; 0.07�Â�±0.09; 0.15�Â�±0.20; -0.01�Â�±0.15; -0.05�Â�±0.10, respectively in the EDOF group (p>0.05). The defocus curve shows continuum VA, smaller 0.2logMAR between -3.0D and 1.0D on the trifocal group and -2.0D to 1.0D (EDOF). Glare & Halo simulations show superior results on the trifocal IOL but no significant differences.

Conclusions:

Both IOLs showed satisfactory visual acuity results on three measured distances with advantages for the trifocal IOL on near visual acuity below 50cm. Unexpectedly, the patients implanted with a trifocal lens do not have an increased glare & halo perception compared to patients with a EDOF lens.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, travel has been funded, fully or partially, by a competing company, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, research is funded, fully or partially, by a competing company, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, receives non-monetary benefits from a competing company., receives non-monetary benefits from a company producing, developing or supplying the product or procedure presented., receives consulting fees, retainer, or contract payments from a competing company